产品
编 号：F146989
分子式：C12H21N3O5S3
分子量：383.51
分子式：C12H21N3O5S3
分子量：383.51
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
250
In-stock
10mg
400
In-stock
50mg
1131
In-stock
100mg
1691
In-stock
结构图
CAS No: 138890-62-7
产品详情
生物活性：
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
体内研究：
Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.The pharmacokinetic parameters of Brinzolamide in rabbits.Intracameral Administration (4.5 mg)Intracameral Administration (4.5 mg)Topical Administration (500 mg)Topical Administration (500 mg)
PK ParametersAqueous HumorIris-Ciliary BodyAqueous HumorIris-Ciliary Body
Tmax (h)0.080.510.25
Cmax (ng/mL, ng/g)11,05019644081245
Terminal t1/2 (h)3.413213.6
AUC0-24h (h*ng/mL, h*ng/g)17,7807725189611414
AUC0-∞ (h*ng/mL, h*ng/g)17,8368839195516628
Dose-normalized AUC0-∞ (h*/mL, h*/g)420.0040.03
Animal Model:Rabbits
Dosage:7.5 mg, 12 mg
Administration:Brinzolamide silicone matrix implant placed in the episcleral space
Result:Resulted in a significant IOP reduction of 4.6 mmHg on days 10-28, with concentrations of 12 mg.
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
体内研究：
Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.The pharmacokinetic parameters of Brinzolamide in rabbits.Intracameral Administration (4.5 mg)Intracameral Administration (4.5 mg)Topical Administration (500 mg)Topical Administration (500 mg)
PK ParametersAqueous HumorIris-Ciliary BodyAqueous HumorIris-Ciliary Body
Tmax (h)0.080.510.25
Cmax (ng/mL, ng/g)11,05019644081245
Terminal t1/2 (h)3.413213.6
AUC0-24h (h*ng/mL, h*ng/g)17,7807725189611414
AUC0-∞ (h*ng/mL, h*ng/g)17,8368839195516628
Dose-normalized AUC0-∞ (h*/mL, h*/g)420.0040.03
Animal Model:Rabbits
Dosage:7.5 mg, 12 mg
Administration:Brinzolamide silicone matrix implant placed in the episcleral space
Result:Resulted in a significant IOP reduction of 4.6 mmHg on days 10-28, with concentrations of 12 mg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备